Drug Approval | April 09, 2025
Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Raichur site is the group’s largest API facility and part of a wider network of seven sites
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
The Alathur facility specializes in the production of Cephalosporin antibiotics
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
